Check for updates

A novel allosteric inhibitor that prevents IKKβ activation†

Hongbo Liu,[a] Hao Liang,[a] Hu Meng,[b] Xiaobing Deng,[a] Xiaoling Zhang[c] and Luhua Lai (ID) *[abc]

I kappa B kinase β (IKKβ) is one of the primary targets to regulate canonical NF-κB activity. The misregulation of NF-κB is associated with various diseases, including chronic inflammation and cancers. Most of the known IKKβ inhibitors target its active form and suffer from poor selectivity. In the present study, we aim to design inhibitors that can bind to the IKKβ inactive form and block its activation. We identified a potential allosteric site between the kinase domain (KD) and ubiquitin-like domain (ULD) of human IKKβ and used it to virtually screen a chemical library for allosteric inhibitors. Among the 133 compounds tested, 16 inhibited NF-κB activity by over 50% at 50 μM in a reporter gene assay. Further quantitative measurements and cytotoxicity study gave one compound **124** (3,4-dichloro-2-ethoxy-*N*-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide) which specifically targets the IKKβ inactive form. In cells, **124** inhibited IκBα phosphorylation and NF-κB transcriptional activity for the reporter gene with an IC_{50} of 35 μM by decreasing the phosphorylation level of Ser177/181 on IKKβ and blocking its activation upon TNFα stimulation. Molecular dynamics simulations demonstrated that **124** binds to the pocket between KD and ULD in the inactive conformation of IKKβ rather than the active conformation. As the first allosteric inhibitor that prevents IKKβ activation, **124** provides a good starting point for further inhibitor discovery and a probe for IKKβ enzyme cycle and regulatory mechanism study.

Introduction

Nuclear factor-kappa B (NF-κB) is an important transcription factor controlling the expression of hundreds of genes associated with inflammation, immune response, cell survival, *etc.* NF-κB can be activated by various stimuli such as tumor necrosis factor (TNF), lipopolysaccharide (LPS), interleukin 1 (IL-1), radiation, pressure and pathogens.[1] The dysfunction of NF-κB is implicated in chronic inflammation, autoimmune disorders and cancer.[2–4] In resting cells, NF-κB is arrested in the cytoplasm by binding to its inhibitor protein IκBα. Upon stimulation, IκBα is phosphorylated by the IKK kinase complex, and then ubiquitinated and degraded by proteasome, liberating free NF-κB into the nucleus to initiate target gene transcription.[5] The IκB kinase (IKK) complex is composed of three major components, two kinases IKKα and IKKβ and a regulatory subunit NEMO. It is generally agreed that IKKβ

plays a key role in activating the NF-κB pathway.[6] IKKβ was considered as a promising pharmaceutical target for drug discovery. Currently known IKKβ inhibitors, including ATP-competitive inhibitors (such as TPCA-1),[7] substrate-competitive inhibitors (BMS-345541)[8] and some natural products (such as ainsliadimer A),[9] all directly interact with the active conformation of IKKβ to block its kinase activity. Three IKKβ inhibitors IMD-1041, CHS-828 and its prodrug EB-1627 have been reported to progress into clinical studies, but none of them have entered into phase III due to various problems. Thus, new strategies for IKKβ inhibitor discovery need to be explored.

IKK activity is controlled by a kinase cycle comprising a poised, an active and an inactive state.[10] Upon the upstream TNFα signal, the poised state IKKβ is activated by the phosphorylation of Ser177 and Ser188 residues on its activation loop. Immediately, self-inhibitory trans-autophosphorylation in the C-terminal of IKKβ significantly reduces its activity. The hyper-phosphorylated inactive kinase then becomes available for a new round of activation through dephosphorylation by phosphatase. And this poised state can be activated again in response to upstream effectors. IKK activity should be tunable by regulating any single steps of this control cycle. Given that the activation of IKK is the precondition for initiating the kinase cycle and critical for the NF-κB activity, inhibiting this

[a] *Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China. E-mail: lhlai@pku.edu.cn*
[b] *BNLMS, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China*
[c] *Center for Quantitative Biology, Peking University, Beijing 100871, China*

† Electronic supplementary information (ESI) available: Supplementary data and experimental methods. See DOI: 10.1039/c7md00599g

This journal is © The Royal Society of Chemistry 2018

Med. Chem. Commun., 2018, **9**, 239–243 | 239

step should be able to block signal transmission to NF-κB most effectively.

The precise mechanisms by which IKKβ becomes phosphorylated and active remain unclear. Two general ideas about this process prevail: one is that there are upstream IKKβ kinases (IKKK) responsible for activating IKKβ, while the other point of view supports that it is possible for IKKβ kinases to autophosphorylate each other. As all currently identified IKKK candidates appear to be dispensable and some of them are cell type specific,[11] IKKβ autophosphorylation seems to be the key step in IKKβ activation. Inhibition of this activation process provides a new opportunity for developing specific IKKβ inhibitors.

In the present study, we aim to discover novel inhibitors that selectively target the activation process of IKKβ using structure-based drug design methods. Fortunately, the inactive conformation of human IKKβ was captured in the X-ray crystal structure of an asymmetric dimer of human IKKβ, which contains one protomer in the active conformation with phosphorylated Ser177 and Ser181, and the other protomer is in the inactive conformation with unphosphorylated Ser177 and Ser181 in the activation loop.[12] Considering the high similarity of active sites in the active and inactive conformations, compounds that bind to the ATP or substrate sites are unlikely to selectively capture the inactive conformation. A unique allosteric site in the inactive conformation might provide a solution to this problem. We set out to search for a potential allosteric site that only exists in the inactive protomer and used it to virtually screen for allosteric inhibitors for IKKβ activation. Compared with conventional orthosteric drugs, allosteric drugs often have higher selectivity and avoid competing with endogenous high concentration substrates and ligands, such as ATP for kinases.[13]

Results and discussion

The crystal structure of human IKKβ (PDB ID: 4KIK) was used for virtual screening. Each chain in the dimer is composed of one kinase domain (KD), one ubiquitin-like domain (ULD) and one scaffold dimerization domain (SDD). We first optimized the crystal structure by completing and refining the missing residues and loops, and then used the Cavity V1.1 program to predict potential ligand binding sites.[14,15] We found one druggable binding site between KD and ULD of the inactive chain with a volume of 551 Å^3 and a predicted maximal pKd of 10.9 (Fig. 1). The pocket is surrounded by three α helixes (R118-S127, L265-L273 and L303-H313) of KD and a loop (T368-L386) between two β sheets of ULD. Similar to TAK1 (transforming growth factor beta-activated kinase 1) activation by TAB (TAK1 binding protein 1),[16] KD–ULD interaction is likely to enhance kinase activity, suggesting that small molecule binding in the pocket between KD and ULD is probable to interfere with the kinase function by disrupting the interaction between these two domains. Furthermore, the extensive interactions between domains in IKKβ have been illustrated important for the activation of

Fig. 1 Predicted allosteric binding site in the inactive IKKβ.

IKKβ.[17] So, we performed virtual screening against this pocket (Fig. 2). The programs Dock6 & AutoDock4 were used to virtually screen about 200 000 compounds in the SPECS library.[18,19] Compounds with a score less than −6.16 kcal mol^{-1} were selected and then subjected to manual selection following the criteria reported previously.[20] A total of 133 compounds were purchased for the cell assay.

The dual-luciferase reporter system was used to evaluate the inhibitory effect of these compounds on NF-κB transcriptional activity upon TNFα stimulation. In the first round of screening, 16 compounds inhibited the NF-κB activity by over 50% at 50 μM. Among them, 7 compounds showed dose-dependent inhibition (Fig. S1†). We measured the IC$_{50}$s of the 5 compounds that passed the PAINS (pan-assay interference compounds) screening,[21] and all of them inhibited luciferase expression at micromolar concentrations (Table S1†).

To eliminate the possible interference from cytotoxicity, the viability of cells treated with the compounds and TNFα with the same concentrations used in the NF-κB luciferase assay was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method (Table S1†). Compound **124** (3,4-dichloro-2-ethoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide) showed NF-κB


Fig. 2 Overview of the virtual screening workflow.

Fig. 3 Compound 124 blocks NF-κB transcription activity towards the luciferase reporter gene in various cells.

Fig. 5 Predicted binding mode of compound 124 in the potential allosteric site of inactive IKKβ. IKKβ is shown as a cyan cartoon. Compound 124 is illustrated in rose red sticks. The key residues from IKKβ are shown in yellow sticks and the predicted hydrogen bonds are displayed in green dashed lines.

inhibition with an IC_{50} of 35 μM in HEK293T and a similar activity in HeLa and SK-N-AS cells with negligible cytotoxicity (Fig. 3). HEK293T and HeLa cells were received from Professor Jincai Luo and Xing Chen (Peking University, China), respectively. SK-N-AS cells were purchased from ATCC. We further demonstrated that 124 blocked IκBα phosphorylation in TNFα-treated HeLa cells with an IC_{50} of 32.7 ± 3.7 μM using the phospho-IκBα (Ser32/36) ELISA Kit (Invitrogen) (the dose–response curve is provided in Fig. S2†). We then tested whether 124 can abrogate the TNFα-induced nuclear translocation of NF-κB/p65. Before TNFα stimulation, compound 124 or fresh medium was pre-incubated with SK-N-AS cells for at least 30 min at 37 °C (5% CO_2). The time lapse images of NF-κB nuclear translocation were captured as described before.[22] At 50 μM, 124 markedly abrogated the TNFα-induced nuclear translocation of NF-κB/p65 (Fig. 4). The bioactivity of 124 was not reported before according to SciFinder. Its purity has been confirmed by ^{1}H-NMR (Fig. S8†) and mass spectra (Fig. S9†).

We further explored possible mechanisms of IKKβ inhibition by 124. The most significant difference between the inactive and active protomer of IKKβ lies in the activation loop, whereas the rest of their structures assume similar conforma-

tions. We performed molecular dynamics (MD) simulations for the apo structure of the asymmetrical IKKβ dimer (for details, see the ESI†). Three trajectories of 100 ns were obtained. Residues in the allosteric site, especially those from the T368-L386 loop, exhibited distinct dynamic characteristics. This loop showed higher flexibility in the active chain than in the inactive chain (the root mean square fluctuations of the two chains are shown in Fig. S4a†). We performed cluster analysis of the conformations from the MD simulations. The T368-L386 loop in the active chain exhibits more diversified conformations than that in the inactive chain (Fig. S4b†). We hypothesize that the allosteric pocket in the active chain might be too flexible to stably accommodate 124. We then docked 124 into both the active and inactive chains in the asymmetrical dimer and performed MD simulations (for details, see the ESI†). Three trajectories of 100 ns were obtained. In the inactive chain, 124 stably binds to the pocket between KD and ULD in all simulations. In contrast, 124 rapidly flies out of the pocket in the active chain in two trajectories after 15 ns simulation. In the third trajectory, 124 dissociates from the pocket and wanders around for most of the time (Fig. S6†). In the trajectories of the inactive chain


Fig. 4 Compound 124 inhibited TNFα-induced NF-κB nuclear translocation in SK-N-AS cells expressing the NF-κB/p65 subunit fused to the red fluorescent protein. Scale bar, 20 μm.

Fig. 6 Compound **124** inhibited IKKβ activation upon TNFα stimulation.

complex, **124** forms a hydrogen bond with the nitrogen atom of the imidazole ring of His380 using the amide hydrogen atom of the pyridine ring, and a hydrogen bond with the main-chain amide hydrogen atom of Leu311 using its sulfonyl oxygen atom for most of the time (Fig. 5 and Table S3†). Our simulations support that **124** inhibits IKKβ activation through stabilizing the inactive conformation and preventing its conversion to the active state.

To confirm that **124** hampers IKKβ activation in cells, we detected the level of active IKKβ in HeLa cells pre-treated with **124** before TNFα induction using western blot analysis (for details, see the ESI†). We found that **124** remarkably decreased the phosphorylation of Ser177/181 on IKKβ, thus blocking IKKβ activation under TNFα stimulation (Fig. 6). Our modeling and experimental studies all indicate that **124** inhibits IKKβ activation.

We further verified this using an *in vitro* kinase assay with activated IKKβ. At 100 μM, **124** shows very weak inhibition of IKKβ kinase activity and no detectable inhibition activity for other 17 kinases (Fig. S7†). This again demonstrates that **124**

Table 1 Analogue screening and activity comparison

ID	Structure	IC$_{50}$[a] (μM)	ID	Structure	IC$_{50}$[a] (μM)
124		35.4 ± 5.3	**A49**		64.3 ± 2.5
A60		>200	**A51**		54.7 ± 3.6
A62		>200	**A50**		>200
A38		71.3 ± 2.0	**A52**		>200
A39		68.0 ± 1.6	**A85**		>200
A4		98.6 ± 3.5	**A88**		>200

[a] The data represent the average and standard deviation (mean ± SD) of triplicate measurements.

selectively inhibits the activation of IKKβ, making it highly selective toward other kinases.

We further searched for analogues of **124** in the SPECS library using the Shape Screening program (Schrödinger 2014-2) with the default settings and compared their inhibition effect on NF-κB transcription activity as described above. Five 2D analogues of **124** and six 3D derivatives were purchased for the cell assay. Among the 11 tested compounds, 5 showed dose-responsive inhibition with micromolar IC$_{50}$s. As shown in Table 1, substituents on both sides of the sulfonamide group significantly affected the compounds' inhibitory activity. Compared to **124**, the inhibitory effect of compounds with piperidinyl substituted by a rigid phenyl ring on the sulfonamide amino group slightly decreased (**A38**, **A39** and **A4**), while compounds with piperidinyl substituted by flexible groups were completely inactive (**A60** and **A62**). Two 3D derivatives **A49** and **A51** displayed similar activity to **124**, and the size of the aromatic group was critical for the inhibition. Compounds with a too small (**A50** and **A52**) or too large (**A85** and **A88**) aryl sulfonamide group almost lost inhibition activity. Based on these analyses, further optimization of **124** can be performed.

Conclusions

In brief, we identified a compound that inhibits the activation of IKKβ for the first time. This compound was discovered by allosteric site prediction, structure-based virtual screen and experimental study. We demonstrate that blocking the activation of IKKβ can effectively prevent NF-κB nuclear translocation. Inhibitors blocking the activation of IKKβ activity provide a novel opportunity for developing selective inhibitors and chemical tools to investigate the molecular mechanisms of IKKβ activation, as well as to develop new drugs against cancer and inflammation.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

Notes and references

1 H. L. Pahl, *Oncogene*, 1999, **18**, 6853–6866.
2 Y. Ben-Neriah and M. Karin, *Nat. Immunol.*, 2011, **12**, 715–723.
3 S. Vallabhapurapu and M. Karin, *Annu. Rev. Immunol.*, 2009, **27**, 693–733.
4 M. Karin, *Nature*, 2006, **441**, 431–436.
5 Q. T. Li and I. M. Verma, *Nat. Rev. Immunol.*, 2002, **2**, 725–734.
6 C. Scheidereit, *Oncogene*, 2006, **25**, 6685–6705.
7 P. L. Podolin, J. F. Callahan, B. J. Bolognese, Y. H. Li, K. Carlson, T. G. Davis, G. W. Mellor, C. Evans and A. K. Roshak, *J. Pharmacol. Exp. Ther.*, 2005, **312**, 373–381.
8 J. R. Burke, M. A. Pattoli, K. R. Gregor, P. J. Brassil, J. F. MacMaster, K. W. McIntyre, X. X. Yang, V. S. Iotzova, W. Clarke, J. Strnad, Y. P. Qiu and F. C. Zusi, *J. Biol. Chem.*, 2003, **278**, 1450–1456.
9 T. Dong, C. Li, X. Wang, L. Dian, X. Zhang, L. Li, S. Chen, R. Cao, L. Li, N. Huang, S. He and X. Lei, *Nat. Commun.*, 2015, **6**, 6522.
10 M. Behar and A. Hoffmann, *Biophys. J.*, 2013, **105**, 231–241.
11 F. Liu, Y. Xia, A. S. Parker and I. M. Verma, *Immunol. Rev.*, 2012, **246**, 239–253.
12 S. Liu, Y. R. Misquitta, A. Olland, M. A. Johnson, K. S. Kelleher, R. Kriz, L. L. Lin, M. Stahl and L. Mosyak, *J. Biol. Chem.*, 2013, **288**, 22758–22767.
13 B. S. DeDecker, *Chem. Biol.*, 2000, 7, R103–R107.
14 Y. Yuan, J. Pei and L. Lai, *J. Chem. Inf. Model.*, 2011, **51**, 1083–1091.
15 Y. Yuan, J. Pei and L. Lai, *Curr. Pharm. Des.*, 2013, **19**, 2326–2333.
16 G. Xu, Y. Lo, Q. Li, G. Napolitano, X. Wu, X. Jiang, M. Dreano, M. Karin and H. Wu, *Nature*, 2011, **472**, 325–330.
17 S. Polley, D. Huang, A. V. Hauenstein, A. J. Fusco, X. Zhong, D. Vu, B. Schroefelbauer, Y. Kim, A. Hoffmann, I. M. Verma, G. Ghosh and T. Huxford, *PLoS Biol.*, 2013, **11**, e1001581.
18 P. T. Lang, S. R. Brozell, S. Mukherjee, E. F. Pettersen, E. C. Meng, V. Thomas, R. C. Rizzo, D. A. Case, T. L. James and I. D. Kuntz, *RNA*, 2009, **15**, 1219–1230.
19 G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell and A. J. Olson, *J. Comput. Chem.*, 2009, **30**, 2785–2791.
20 Q. Wang, Y. Qi, N. Yin and L. Lai, *PLoS One*, 2014, **9**, e94829.
21 J. B. Baell and G. A. Holloway, *J. Med. Chem.*, 2010, **53**, 2719–2740.
22 X. Zhang, N. Yin, A. Guo, Q. Zhang, Y. Zhang, Y. Xu, H. Liu, B. Tang and L. Lai, *Biochem. Biophys. Res. Commun.*, 2017, **489**, 287–292.